Greenleaf Trust Has $562,000 Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Greenleaf Trust lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,938 shares of the biopharmaceutical company’s stock after purchasing an additional 405 shares during the period. Greenleaf Trust’s holdings in Alnylam Pharmaceuticals were worth $562,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Harbor Capital Advisors Inc. lifted its holdings in Alnylam Pharmaceuticals by 1.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock valued at $562,000 after buying an additional 51 shares during the period. EP Wealth Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 6.4% in the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 71 shares during the period. Oppenheimer & Co. Inc. lifted its holdings in Alnylam Pharmaceuticals by 2.1% in the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock valued at $800,000 after buying an additional 93 shares during the period. Xponance Inc. lifted its holdings in Alnylam Pharmaceuticals by 0.7% in the third quarter. Xponance Inc. now owns 14,984 shares of the biopharmaceutical company’s stock valued at $2,654,000 after buying an additional 109 shares during the period. Finally, Quent Capital LLC lifted its holdings in Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ALNY. The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $230.00 to $173.00 in a research note on Friday, February 16th. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $165.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Finally, JPMorgan Chase & Co. upped their target price on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research note on Thursday, February 1st. Nine equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $216.12.

Alnylam Pharmaceuticals Trading Up 1.0 %

Shares of ALNY opened at $145.79 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $143.50 and a 12 month high of $218.88. The firm has a fifty day simple moving average of $151.09 and a 200 day simple moving average of $166.50. The stock has a market capitalization of $18.36 billion, a price-to-earnings ratio of -40.95 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. During the same quarter in the previous year, the company posted ($1.68) EPS. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.